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Summary 
The activity of ADAMTS13, the von Willebrand factor (VWF) 
cleaving protease is low in several conditions, including HELLP 
(haemolysis, elevated liver enzymes, and low platelet count) syn-
drome.  As HELLP syndrome develops in most cases on the basis 
of preeclampsia, our aim was to determine whether plasma 
ADAMTS13 activity is decreased in preeclampsia. Sixty-seven 
preeclamptic patients, 70 healthy pregnant women and 59 
healthy non-pregnant women were involved in this case-control 
study. Plasma ADAMTS13 activity was determined with the 
FRETS-VWF73 assay, while VWF antigen (VWF:Ag) levels with 
an enzyme-linked immunosorbent assay.  The multimeric pattern 
of  VWF was analyzed by SDS-agarose gel electrophoresis. 
 There was no significant difference in plasma ADAMTS13 activ-
ity between the preeclamptic and the healthy pregnant and non-
pregnant groups (median [25–75 percentile]: 98.8 [76.5–112.8] 
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%, 96.3 [85.6–116.2] % and 91.6 [78.5–104.4] %, respectively; 
p>0.05). However, plasma VWF:Ag levels were significantly 
higher in preeclamptic patients than in healthy pregnant and 
non-pregnant women (187.1 [145.6–243.1] % versus 129.3 
[105.1–182.8] % and 70.0 [60.2–87.3] %, respectively; p<0.001). 
The multimeric pattern of  VWF was normal in each group. 
Primiparas had lower plasma ADAMTS13 activity than multi-
paras (92.6 [75.8–110.6] % versus 104.2 [92.1–120.8] %; 
p=0.011). No other relationship was found between clinical 
characteristics, laboratory parameters and plasma ADAMTS13 
activity in either study group. In conclusion, plasma ADAMTS13 
activity is normal in preeclampsia despite the increased VWF:Ag 
levels. However, further studies are needed to determine 
whether a decrease in plasma ADAMTS13 activity could predis-
pose preeclamptic patients to develop HELLP syndrome. 
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Introduction 
Preeclampsia is a severe complication of human pregnancy with 
a worldwide incidence of 2–10% (1). It is one of the leading 
causes of maternal, as well as perinatal morbidity and mortality, 
even in developed countries. Despite intensive research efforts, 
the etiology and pathogenesis of preeclampsia are not fully 
understood. Increasing evidence suggests that an excessive ma-
ternal systemic inflammatory response to pregnancy with acti-
vation of endothelial cells plays a crucial role in the pathogenesis 
of the disease (2). The development of preeclampsia is in-
fluenced by both genetic and environmental risk factors, sug-
gesting its multifactorial inheritance (3). 
ADAMTS13 (A Disintegrin-like And Metalloprotease with 
ThromboSpondin type 1 motif, member 13), a circulating zinc 
metalloprotease, cleaves von Willebrand factor (VWF) when-
ever its cleavage site at the peptide bond between tyrosine at 
position 1605 and methionine at position 1606 in the VWF A2 
domain is exposed by shear stress. This proteolysis converts en-
dothelial-derived, newly secreted ultralarge VWF multimers into 
smaller, less reactive derivatives (4, 5). ADAMTS13 is syn-
thesized mainly in hepatic stellate cells, but variable expression 
was observed in other cell types, including endothelial cells and 
platelets (6–8). 
A profound deficiency of ADAMTS13, due to genetic mu-
tations or autoimmune inhibition, impairs VWF cleavage, lead-
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ing in turn to the disseminated formation of platelet-rich throm-
bi in the microcirculation and to symptoms of end-organ ische-
mia, characteristics of thrombotic thrombocytopenic purpura 
(TTP). However, a substantial proportion of patients with TTP, 
particularly of those with the acquired form, have detectable and 
even normal plasma ADAMTS13 activity (9, 10). On the other 
hand, the VWF-cleaving protease activity is also low in several 
physiological and pathological conditions, most of which are as-
sociated with an increased thrombotic tendency, organ involve-
ment and/or acute phase reaction (11–21). Nevertheless, a severe 
deficiency in plasma ADAMTS13 activity (less than 5% of nor-
mal) seems to be a specific beacon of TTP (22). 
Preeclampsia is also characterized by systemic inflammation 
with an acute phase reaction, multi-organ involvement and a pro-
thrombotic state, as well as by increased production of the pro-
tease’s substrate, VWF by activated endothelial cells. In addition, 
reduced ADAMTS13 activity has been observed previously in 
pregnant women with HELLP (haemolysis, elevated liver 
enzymes, and low platelet count) syndrome (23, 24). HELLP 
syndrome develops in most cases on the basis of preeclampsia 
and is one of its most severe complications. However, 
ADAMTS13 activity has not been investigated yet in a large 
number of preeclamptic patients without HELLP syndrome. 
Therefore, our aim was to determine whether plasma 
ADAMTS13 activity is decreased in preeclampsia. We also 
measured VWF antigen (VWF:Ag) levels in the same samples 
and examined the relationship of clinical characteristics, stan-
dard laboratory parameters and plasma VWF:Ag levels to plas-
ma ADAMTS13 activity. The multimeric pattern of VWF was 
also analyzed in our study groups. 
Materials and methods 
Study patients 
Our study was designed employing a case-control approach. 
Sixty-seven preeclamptic patients, 70 healthy pregnant women 
with uncomplicated pregnancies and 59 healthy non-pregnant 
women were involved in the study. The study participants were 
enrolled in the 1st Department of Obstetrics and Gynecology and 
in the Department of Obstetrics and Gynecology of Kútvölgyi 
Clinical Center, at the Semmelweis University, Budapest, Hun-
gary. All women were Caucasian and resided in the same geo-
graphic area in Hungary. Exclusion criteria were multifetal ges-
tation, chronic hypertension, diabetes mellitus, autoimmune dis-
ease, angiopathy, renal disorder, maternal or fetal infection and 
fetal congenital anomaly. The women were fasting, none of the 
pregnant women were in active labor, and none had rupture of 
membranes. The healthy non-pregnant women were in the early 
follicular phase of the menstrual cycle (between cycle days 3 and 
5), and none of them received hormonal contraception. 
 Preeclampsia was defined by increased blood pressure (≥140 
mmHg systolic or ≥90 mmHg diastolic on ≥2 occasions at least 6 
hours [h] apart) that occurred after 20 weeks of gestation in a 
woman with previously normal blood pressure, accompanied by 
proteinuria (≥0.3 g/24 h). Blood pressure returned to normal by 
12 weeks postpartum in each preeclamptic study patient. Pre-
eclampsia was regarded as severe if any of the following criteria 
was present: blood pressure ≥160 mmHg systolic or ≥110 mmHg 
diastolic, or proteinuria ≥5 g/24 h. Pregnant women with eclamp-
sia or HELLP syndrome were not enrolled in this study. Early 
onset of preeclampsia was defined as onset of the disease before 
34 weeks of gestation (between 20 and 33 completed gestational 
weeks). Fetal growth restriction was diagnosed if the fetal birth 
weight was below the 10th percentile for gestational age and 
gender, based on Hungarian birth weight percentiles (25). 
 The study protocol was approved by the Regional, Institu-
tional Committee of Medical Ethics at the Semmelweis Univer-
sity, and written informed consent was obtained from each pa-
tient. The study was conducted in accordance with the Declar-
ation of Helsinki. 
Biological samples 
Blood samples were obtained from an antecubital vein into 
native, as well as EDTA- or sodium citrate anticoagulated tubes 
and centrifuged at room temperature with a relative centrifugal 
force of 3,000 g for 10 minutes (min). The aliquots of serum and 
plasma were stored at –80°C until the analyses were performed. 
Determination of plasma ADAMTS13 activity 
The fluorigenic substrate, FRETS-VWF73, was purchased from 
Peptides International (Louisville, KY, USA) and applied for the 
determination of ADAMTS13 enzyme activity according to the 
protocol provided by the supplier with minor modifications (26). 
Briefly, the test citrated plasma were diluted 1:20 in assay buffer 
(5 mM Bis-Tris, 25 mM CaCl2, 0.005% Tween 20, pH 6.0) and 
mixed with 5 µM FRETS-VWF73 substrate solution (20 µl 
each), in white 384-well plates. Fluorescence was measured at 
37°C every 2 min for 1 h in Chameleon microplate reader 
(Hidex, Turku, Finland) equipped with a 340 nm excitation and a 
460 nm emission filter. The reaction rate was calculated by linear 
regression analysis of fluorescence over time. A two-fold dilu-
tion series of normal human plasma (mixed from citrated plasma 
samples of 10 healthy blood donors) was applied as standard 
curve, 100% ADAMTS13 activity was set at the reaction rate ob-
served in the 1:20 diluted sample. The intra-assay coefficient of 
variation (CV) was <5%, the inter-assay CV was 6–9% 
(measured at 60 and 100% activity levels). 
In six plasma samples, we also measured ADAMTS13 
enzyme activity with the collagen-binding assay, as described by 
Gerritsen et al. (1999) (27). Pooled citrated plasma of 10 healthy 
blood donors was used as reference. The results of the FRETS-
VWF73 assay showed good agreement with those of the col-
lagen-binding method (Spearman R=0.82; p<0.05). 
Determination of plasma VWF antigen (VWF:Ag) 
levels 
VWF antigen (VWF:Ag) levels were measured in citrated plas-
ma by an enzyme-linked immunosorbent assay (ELISA) using 
commercially available antibodies (Dakopatts, Glostrup, Den-
mark). Microtiter plates (Immunoplate Maxisorb, Nunc, Ros-
kilde, Denmark) were coated with polyclonal rabbit anti-human 
VWF antibody diluted 1:800 in sodium bicarbonate buffer, pH 
9.6. After overnight incubation at 4°C, plates were washed in 
Tris-buffered saline containing 0.05% Tween 20 (TBS-T). The 
plates were incubated with plasma samples diluted 1:500 or stan-
dard control plasma (dilution range 1:250 to 1:8,000) for 2 h at 
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room temperature. After washes with TBS-T, horse radish per-
oxidase (HRP)-conjugated polyclonal rabbit anti-human VWF 
antibody was added to the plates and incubated for 1 h, followed 
by addition of ortho-phenylenediamine (OPD). The optical den-
sity was measured at 492 nm. Results are expressed as percen-
tages of a standard composed of pooled human plasma of 10 
healthy blood donors. 
Multimeric analysis of VWF 
The multimeric pattern of VWF was analyzed in EDTA plasma 
samples by sodium dodecyl sulphate (SDS)-agarose gel electro-
phoresis. Briefly, low resolution (0.8%) agarose (Seakem HGT, 
Lonza, Basel, Switzerland) gels were cast on glass plates, using 
Tris-Borate buffers as recommended by the manufacturer of the 
agarose. Electrophoresis was performed at constant current for 6 
h at 20 mA/gel on a plate cooled to 18°C. Proteins were trans-
ferred to PVDF membranes (Immobilon-P, Millipore Corp., 
Bedford, MA, USA) by tank electro-blotting method. To enhance 
the transfer of the largest VWF molecules, VWF multimers were 
degraded by treating the gels for 10 min with 1 mM β-mercap-
toethanol (mercaptolysis) before blotting (28). VWF was visual-
ized by immunostaining using HRP-labelled polyclonal rabbit 
anti-human VWF antibody (DakoCytomation, Glostrup, Den-
mark) and DAB substrate. 
Quantitative multimer analysis was performed similarly to 
Budde et al. (2008) (29). Briefly, membranes were digitalized by 
GS-800 (Bio-Rad Laboratories, Richmond, CA, USA) cali-
brated densitometer, and processed by the QuantityOne software 
(Bio-Rad Laboratories). The percentage of large multimers – de-
fined as oligomers larger than the 20-mer (band 10) – was calcu-
lated using the reflective density against relative front data, and 
was used for the description of VWF multimer distribution. 
Determination of other laboratory parameters 
Standard laboratory parameters were measured by Roche Inte-
gra 800 autoanalyzer (clinical chemistry, C-reactive protein) or 
by Cell-Dyn 3500 hematology analyzer (platelet count). 
Statistical analysis 
The normality of continuous variables was assessed using the 
Shapiro-Wilk’s W-test. As the continuous variables were not 
normally distributed, non-parametric statistical methods were 
Table 1: Clinical characteristics, standard 
laboratory parameters, plasma 
ADAMTS13 activity and von Willebrand 
factor antigen (VWF:Ag) levels of 
healthy non-pregnant and pregnant 
women and preeclamptic patients. 







Age (years) 028 (23–35) 0030 (28–32) 0029 (26–33) 
BMI at blood draw (kg/m2) 020.8 (19.6–22.9) 0025.9 (24.2–27.7)b 0030.0 (27.7–33.3)b,d 
Smokers 014 (23.7%) 0000 (0%)b 0003 (4.5%)a 
Primiparas n.a. 0045 (64.3%) 0043 (64.2%) 
Systolic blood pressure (mmHg) 115 (110–120) 0110 (105–120)a 0160 (154–180)b,d 
Diastolic blood pressure (mmHg) 080 (70–80) 0070 (60–80)b 0100 (97–110)b,d 
Serum creatinine level (µM) 066 (61–72) 0047 (41–51)b 0063 (55–70)d 
Serum bilirubin level (µM) 009.3 (6.6–12.4) 0005.1 (3.8–6.6)b 0007.4 (5.8–9.3)a,d 
Serum AST activity (U/l) 017 (15–20) 0019 (16–21) 0019 (15–24) 
Serum ALT activity (U/l) 014 (12–17) 0012 (10–16) 0015 (11–21)c 
Serum LDH activity (U/l) 154 (128–170) 0159 (131–174) 0192 (155–225)b,d 
Serum CRP level (mg/l) 000.7 (0.5–1.8) 0003.6 (1.7–7.3)b 0006.7 (3.0–12.1)b,c 
Plasma ADAMTS13 activity (%) 091.6 (78.5–104.4) 0096.3 (85.6–116.2) 0098.8 (76.5–112.8) 
Plasma VWF:Ag level (%) 070.0 (60.2–87.3) 0129.3 (105.1–182.8)b 0187.1 
(145.6–243.1)b,d 
Data are presented as median (25–75 percentile) for continuous variables and as number (percent) for categorical variables. n.a.:  
not applicable; ADAMTS13: A Disintegrin-like And Metalloprotease with ThromboSpondin type 1 motif, member 13; BMI:  
body mass index; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH:  
lactate dehydrogenase; CRP: C-reactive protein; VWF:Ag: von Willebrand factor antigen. a p<0.05 versus healthy non-pregnant  
women. b p<0.001 versus healthy non-pregnant women. c p<0.05 preeclamptic patients versus healthy pregnant women. d p<0.001  

















 Gestational age at blood draw  
(weeks) 
n.a. 0035 (30–36) 0038 (36–39)d 
 Gestational age at delivery  
(weeks) 
n.a. 0039 (38–40) 0038 (37–40)c 
 Fetal birth weight (grams) n.a. 3500 (3200–3800) 3200 (2450–3600)d 
 Fetal growth restriction n.a. 0000 (0%) 0011 (16.4%)d 
 Platelet count (cells/µl) 194 (170–225) 0192 (168–221) 0214 (186–254)a,c 
 Serum BUN level (mM) 004.1 (3.5–4.8) 0002.7 (2.1–3.2)b 0003.4 (2.7–4.1)a,d 
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used. To compare continuous variables between two groups, the 
Mann-Whitney U-test was applied, whereas to compare them 
among multiple groups, the Kruskal-Wallis analysis of variance 
(ANOVA) by ranks test was performed. Multiple comparisons of 
mean ranks for all groups were carried out as post-hoc tests. The 
Fisher exact and Pearson Chi2 tests were used to compare cat-
egorical variables between groups. The Spearman rank order 
correlation was applied to calculate correlation coefficients. As 
plasma ADAMTS13 activity and VWF:Ag levels showed a 
skewed distribution, we performed analysis of covariance (AN-
COVA) and multiple linear regression analysis with logarithmi-
cally transformed data. 
Statistical analyses were carried out using the following soft-
ware: STATISTICA (version 7.1; StatSoft, Inc., Tulsa, OK, 
USA) and Statistical Package for the Social Sciences (version 
15.0 for Windows; SPSS, Inc., Chicago, IL, USA). For all statis-
tical analyses, p<0.05 was considered statistically significant. 
In the article, data are reported as median (25–75 percentile) 
for continuous variables and as number (percent) for categorical 
variables. 
Results 
Patient characteristics and standard laboratory 
parameters 
The clinical characteristics and standard laboratory parameters 
of the study participants are described in Table 1. There was no 
statistically significant difference in age between preeclamptic 
patients and healthy pregnant and non-pregnant women. How-
ever, as shown in Table 1, most of the clinical features and 
measured laboratory parameters differed significantly among 
the three study groups. Nevertheless, no significant difference 
was observed in the percentage of patients with blood group 0 
between the preeclamptic and the healthy pregnant and non-
pregnant groups (data not shown). 
Plasma ADAMTS13 activity, VWF:Ag levels and VWF 
multimeric pattern 
The results of the ADAMTS13 and VWF:Ag assays are dis-
played in Table 1, Figure 1A and B. No significant difference was 
found in plasma ADAMTS13 activity among the three study 
A 
B 
Figure 1: Plasma ADAMTS13 activity (A) 
and von Willebrand factor antigen 
(VWF:Ag) levels (B) of healthy non-preg-
nant and pregnant women and pre-
eclamptic patients. Middle point: median; 
Box: interquartile range (25–75 percentile); 
Whisker: range. 
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groups. However, plasma VWF antigen levels were significantly 
higher in preeclamptic patients than in healthy pregnant and non-
pregnant women. Adjustment for age, body mass index (BMI) 
and gestational age at blood draw in analyses of covariance (AN-
COVA) did not change these results. The preeclamptic and 
healthy pregnant groups were divided into gestational age sub-
groups, since gestational age at blood draw was significantly dif-
ferent between the two groups. Plasma ADAMTS13 activity and 
VWF:Ag levels were also compared between the two study 
groups in these gestational age categories, separately. There were 
no significant differences in plasma ADAMTS13 activity be-
tween preeclamptic patients and healthy pregnant women in any 
of these categories. Nevertheless, preeclamptic patients had sig-
nificantly higher plasma VWF:Ag levels than normotensive, 
healthy pregnant women in each gestational age category. 
 In the group of preeclamptic patients, no statistically signifi-
cant differences were observed in plasma ADAMTS13 activity 
and VWF:Ag levels between patients with mild and severe pre-
eclampsia, between patients with late and early onset of the dis-
ease, or between preeclamptic patients with and without fetal 
growth restriction (data not shown). 
 We determined the multimeric pattern of VWF in five pre-
eclamptic patients, five healthy pregnant women and five 
healthy non-pregnant women, who were matched for age, ges-
tational age and smoking status. The VWF multimeric pattern 
was found to be normal in each studied woman. The percentage 
of large multimers did not show significant difference between 
the preeclamptic and the healthy pregnant and non-pregnant 
women (median (range): 24.7 (18.5–33.7) %, 27.3 (22.2–30.2) 
% and 25.5 (20.2–28.8) %, respectively; p=0.45). Representative 
examples of the intact multimeric structure of VWF in our study 
groups are presented in Figure 2. 
Relationship of clinical characteristics, standard 
laboratory parameters and plasma VWF:Ag levels 
to plasma ADAMTS13 activity 
We also investigated whether clinical characteristics, standard 
laboratory parameters and plasma VWF:Ag levels are related to 
plasma ADAMTS13 activity in our study groups. There was a 
trend for primiparas to have lower plasma ADAMTS13 activity 
than multiparas both in the healthy pregnant and the preeclamp-
tic groups, and this association reached statistical significance in 
the total group of pregnant women involved in the study (medi-
an 25–75 percentile): 92.6 (75.8–110.6) % versus 104.2 
(92.1–120.8) %; p=0.011). There was a statistically significant 
negative correlation between plasma VWF:Ag levels and 
ADAMTS13 activity in the group of preeclamptic patients 
(Spearman R=-0.26; p=0.040), but the significance disappeared 
after adjustment for maternal age, primiparity, BMI and ges-
tational age at blood draw in multiple linear regression analysis 
(standardized regression coefficient (β)=-0.11; p=0.48). Never-
theless, no significant correlations were found between these 
two variables either in the groups of healthy pregnant and non-
pregnant women, or in the total group of study participants (Fig. 
3). There was no other relationship between clinical features and 
measured laboratory parameters of the study subjects and plas-
ma ADAMTS13 activity in either study group. 
Discussion 
In the present study, we did not find a significant difference in plas-
ma ADAMTS13 activity between preeclamptic patients and 
healthy pregnant and non-pregnant women, whereas plasma VWF 
antigen levels were significantly higher in the preeclamptic group 
compared with the healthy pregnant and non-pregnant groups. The 
multimeric pattern of VWF was normal both in preeclamptic pa-
tients and healthy pregnant and non-pregnant women. 
 Lattuada et al. (2003) reported significantly lower plasma 
ADAMTS13 activity in patients with HELLP syndrome com-
Figure 2: Representative examples of the intact multimeric 
structure of von Willebrand factor (VWF) in healthy non-preg-
nant women (H), healthy pregnant women (N) and preeclamp-
tic patients (P) (C: fresh pooled plasma of (5) healthy volun-
teers; S: Dade Behring Standard Human Plasma). 
Figure 3: Scatterplot of plasma ADAMTS13 activity versus  
von Willebrand factor antigen (VWF:Ag) levels in healthy non-
pregnant and pregnant women and preeclamptic patients. 
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stein et al. (2006), preeclamptic patients with HELLP syndrome 
were primarily investigated and only six preeclamptic patients 
without HELLP syndrome were enrolled. The authors concluded 
that acute endothelial cell activation in HELLP syndrome and 
decreased ADAMTS13 activity result in increased amounts of 
active VWF. This could explain the consumptive thrombocy-
topenia and the formation of platelet-rich thrombi in HELLP 
syndrome. 
 The most remarkable observation of our study is that, despite 
the significantly higher plasma VWF antigen levels, plasma 
VWF cleaving protease activity is normal in preeclampsia. In 
several conditions associated with an increased plasma VWF 
antigen level, ADAMTS13 activity was found to be low pre-
viously (12, 14, 15, 17, 18, 30–32). However, the biological sig-
nificance of these observations is uncertain. The inverse relation 
may be due to consumption of the protease when its substrate is 
present in high concentrations or sequestration of ADAMTS13 
to the vascular endothelial cells when the latter are secreting in-
creasing amounts of VWF (33–35). Nevertheless, in accordance 
with our findings, the VWF cleaving protease activity is not al-
ways low when plasma VWF:Ag level is high, or vice versa (16). 
The mechanisms regulating ADAMTS13 activity are not 
completely understood at present, particularly in pregnancy, 
where the role of placental hormones needs also to be considered. 
According to our results, consumptive regulation by increased 
VWF:Ag levels seems to be a secondary phenomenon in pre-
eclampsia, as suggested by the lack of correlation between 
VWF:Ag levels and ADAMTS13 activity in the adjusted model. 
Furthermore, liver and renal failure, as well as disseminated in-
travascular coagulation (DIC) were absent in our preeclamptic 
group, and serum C-reactive protein levels were only slightly in-
creased, which are consistent with normal plasma ADAMTS13 
activity. Additionally, ultralarge VWF multimers were not present 
in the plasma of our preeclamptic patients, which also supports 
the absence of a severe ADAMTS13 deficiency in preeclampsia. 
Taken together, our results indicate that ADAMTS13 activity is 
differentially regulated in preeclampsia from VWF:Ag level, the 
marker of endothelial activation/dysfunction (36). 
 A key issue is why certain patients with preeclampsia devel-
op the serious, even life-threatening condition, the syndrome of 
haemolysis, elevated liver enzymes, and low platelet count. 
HELLP syndrome is a distinct entity and is characterized by a 
much more intensive systemic inflammation than preeclampsia 
with more pronounced endothelial injury and signs of a compen-
sated DIC, all of which are known to influence plasma 
ADAMTS13 activity (37, 38). Interestingly, an association has 
been observed previously between ADAMTS13 deficiency and 
the severity of inflammatory host response independently of its 
origin. Low ADAMTS13 activity was supposed to contribute to 
both activation of coagulation and platelets in patients with se-
vere sepsis, resulting in consumptive thrombocytopenia (19). 
VWF and its cleaving protease appear to interact to form a 
fine-tuned VWF/ADAMTS13 system. In patients developing 
HELLP syndrome, the transition from chronic endothelial acti-
vation – characteristic of preeclampsia – to acute activation could 
result in increased levels of newly released, active VWF (24). On 
the basis of our findings along with those of Lattuada et al. (2003) 
and Hulstein et al. (2006), we hypothesize that the combined 
What is known about this topic? 
– The activity of ADAMTS13 is low in several physiologi-
cal and pathological conditions, most of which are associ-
ated with an increased thrombotic tendency, organ in-
volvement and/or acute phase reaction. However, a severe 
deficiency in plasma ADAMTS13 activity seems to be a 
specific beacon of thrombotic thrombocytopenic purpura. 
− Plasma ADAMTS13 activity is significantly lower in pa-
tients with HELLP (haemolysis, elevated liver enzymes, 
and low platelet count) syndrome than in healthy preg-
nant and non-pregnant women. 
− While plasma levels of the protease’s substrate, von 
Willebrand factor, are well known to be increased in pre-
eclampsia, plasma ADAMTS13 activity has not been in-
vestigated yet in a large number of preeclamptic patients 
without HELLP syndrome. 
What does this paper add? 
− Plasma ADAMTS13 activity is normal in preeclampsia 
despite the increased von Willebrand factor antigen lev-
els. 
− In the group of preeclamptic patients, there are no statis-
tically significant differences in plasma ADAMTS13 ac-
tivity between patients with mild and severe preeclamp-
sia, between patients with late and early onset of the dis-
ease, or between preeclamptic patients with and without 
fetal growth restriction. 
− Primiparas have lower plasma ADAMTS13 activity than 
multiparas. There is no other relationship between clinical 
characteristics and laboratory parameters of preeclamptic 
patients, including VWF:Ag levels, and plasma 
ADAMTS13 activity.
pared to healthy pregnant and non-pregnant women (23). The re-
duced levels were not due to the presence of inactivating auto-
antibodies and returned to normal on remission. Additionally, 
the plasma VWF antigen levels, ristocetin cofactor and collagen 
binding activities were significantly higher than in normal preg-
nancy, but ultralarge VWF multimers were not present in plasma. 
The authors hypothesized that high VWF levels account for the 
decrease of ADAMTS13 activity in plasma, as a result of the 
consumption of the protease when high levels of the substrate 
must be disposed. However, preeclamptic patients were not in-
volved in this study. 
The findings of Lattuada et al. (2003) were confirmed by the 
study of Hulstein et al. (2006) (24). They observed significantly 
increased plasma VWF antigen, active VWF levels as well as ris-
tocetin cofactor activity (VWF:RCo) and moderately but signifi-
cantly decreased plasma ADAMTS13 activity in preeclamptic 
patients with HELLP syndrome compared with healthy pregnant 
volunteers. Preeclamptic patients without HELLP syndrome 
were found to have significantly higher plasma VWF antigen 
levels than healthy pregnant women, while their plasma active 
VWF levels, ristocetin cofactor (VWF:RCo) and ADAMTS13 
activities were similar to those of controls, which is in complete 
agreement with our findings. Nevertheless, in the study of Hul-
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presence of increased VWF levels and low ADAMTS13 activity 
with the thrombotic tendency of pregnancy could lead to the 
formation of platelet-rich microthrombi and consumptive throm-
bocytopenia with the development of HELLP syndrome. This hy-
pothesis might also explain – at least partly – the success of plas-
ma exchange (with replacement of ADAMTS13) in refractory 
postpartum cases. Moreover, if ADAMTS13 deficiency were 
proven to have a causative role in the pathogenesis of HELLP 
syndrome, application of recombinant ADAMTS13 preparations 
might be an alternative treatment of choice, particularly in the 
early third trimester and the postpartum period. Nevertheless, ex-
perimental studies are required to support our hypothesis with 
mechanistic information. 
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 In conclusion, plasma VWF cleaving protease 
(ADAMTS13) activity is normal in preeclampsia despite the in-
creased VWF:Ag levels. However, further prospective studies 
are needed to determine whether a decrease in plasma 
ADAMTS13 activity precedes the development of HELLP syn-
drome in preeclamptic patients, and thus can help to predict this 
serious complication in preeclampsia. 
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